212 related articles for article (PubMed ID: 30553520)
1. Miniaturised 'antibody'-drug conjugates for solid tumours?
Deonarain MP
Drug Discov Today Technol; 2018 Dec; 30():47-53. PubMed ID: 30553520
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.
Malik P; Phipps C; Edginton A; Blay J
Pharm Res; 2017 Dec; 34(12):2579-2595. PubMed ID: 28924691
[TBL] [Abstract][Full Text] [Related]
3. Exploring alternative antibody scaffolds: Antibody fragments and antibody mimics for targeted drug delivery.
Richards DA
Drug Discov Today Technol; 2018 Dec; 30():35-46. PubMed ID: 30553519
[TBL] [Abstract][Full Text] [Related]
4. Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?
Deonarain MP; Yahioglu G; Stamati I; Pomowski A; Clarke J; Edwards BM; Diez-Posada S; Stewart AC
Antibodies (Basel); 2018 Mar; 7(2):. PubMed ID: 31544868
[TBL] [Abstract][Full Text] [Related]
5. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
Chen H; Lin Z; Arnst KE; Miller DD; Li W
Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044
[TBL] [Abstract][Full Text] [Related]
6. Antibody-Drug Conjugates for Tumor Targeting-Novel Conjugation Chemistries and the Promise of non-IgG Binding Proteins.
Merten H; Brandl F; Plückthun A; Zangemeister-Wittke U
Bioconjug Chem; 2015 Nov; 26(11):2176-85. PubMed ID: 26086208
[TBL] [Abstract][Full Text] [Related]
7. Natural products as exquisitely potent cytotoxic payloads for antibody- drug conjugates.
Gromek SM; Balunas MJ
Curr Top Med Chem; 2015; 14(24):2822-34. PubMed ID: 25487009
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
Tsuchikama K; An Z
Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
[TBL] [Abstract][Full Text] [Related]
9. Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate.
Puthenveetil S; He H; Loganzo F; Musto S; Teske J; Green M; Tan X; Hosselet C; Lucas J; Tumey LN; Sapra P; Subramanyam C; O'Donnell CJ; Graziani EI
PLoS One; 2017; 12(5):e0178452. PubMed ID: 28558059
[TBL] [Abstract][Full Text] [Related]
10. Tackling solid tumour therapy with small-format drug conjugates.
Deonarain MP; Xue Q
Antib Ther; 2020 Dec; 3(4):237-245. PubMed ID: 33928231
[TBL] [Abstract][Full Text] [Related]
11. Antibody-drug conjugate payloads.
Anderl J; Faulstich H; Hechler T; Kulke M
Methods Mol Biol; 2013; 1045():51-70. PubMed ID: 23913141
[TBL] [Abstract][Full Text] [Related]
12. Emerging formats for next-generation antibody drug conjugates.
Deonarain MP; Yahioglu G; Stamati I; Marklew J
Expert Opin Drug Discov; 2015 May; 10(5):463-81. PubMed ID: 25797303
[TBL] [Abstract][Full Text] [Related]
13. A size exclusion-reversed phase two dimensional-liquid chromatography methodology for stability and small molecule related species in antibody drug conjugates.
Li Y; Gu C; Gruenhagen J; Zhang K; Yehl P; Chetwyn NP; Medley CD
J Chromatogr A; 2015 May; 1393():81-8. PubMed ID: 25818558
[TBL] [Abstract][Full Text] [Related]
14. Physical and Chemical Stability of Antibody Drug Conjugates: Current Status.
Ross PL; Wolfe JL
J Pharm Sci; 2016 Feb; 105(2):391-397. PubMed ID: 26869406
[TBL] [Abstract][Full Text] [Related]
15. Peptide-Drug Conjugate: A Novel Drug Design Approach.
Ma L; Wang C; He Z; Cheng B; Zheng L; Huang K
Curr Med Chem; 2017; 24(31):3373-3396. PubMed ID: 28393694
[TBL] [Abstract][Full Text] [Related]
16. The next generation of antibody drug conjugates.
Mack F; Ritchie M; Sapra P
Semin Oncol; 2014 Oct; 41(5):637-52. PubMed ID: 25440608
[TBL] [Abstract][Full Text] [Related]
17. Current strategies for the discovery and bioconjugation of smaller, targetable drug conjugates tailored for solid tumor therapy.
Deonarain MP; Yahioglu G
Expert Opin Drug Discov; 2021 Jun; 16(6):613-624. PubMed ID: 33275475
[No Abstract] [Full Text] [Related]
18. Novel formats of antibody conjugates: recent advances in payload diversity, conjugation, and linker chemistry.
Fujii T; Matsuda Y
Expert Opin Biol Ther; 2023; 23(11):1053-1065. PubMed ID: 37953519
[TBL] [Abstract][Full Text] [Related]
19. Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates.
Puthenveetil S; Musto S; Loganzo F; Tumey LN; O'Donnell CJ; Graziani E
Bioconjug Chem; 2016 Apr; 27(4):1030-9. PubMed ID: 26942771
[TBL] [Abstract][Full Text] [Related]
20. Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics.
Thompson P; Fleming R; Bezabeh B; Huang F; Mao S; Chen C; Harper J; Zhong H; Gao X; Yu XQ; Hinrichs MJ; Reed M; Kamal A; Strout P; Cho S; Woods R; Hollingsworth RE; Dixit R; Wu H; Gao C; Dimasi N
J Control Release; 2016 Aug; 236():100-16. PubMed ID: 27327768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
